Breast Cancer Research and Treatment最新文献

{"title":"Diffuse reflectance and fluorescence spectroscopy for breast conserving surgery.","authors":"Dhurka Shanthakumar, Vadzim Chalau, Yufeng Shi, Ria Ranjitkar, Anna Silvanto, Ara Darzi, Daniel R Leff, Daniel S Elson","doi":"10.1007/s10549-025-07790-8","DOIUrl":"10.1007/s10549-025-07790-8","url":null,"abstract":"<p><strong>Purpose: </strong>The major challenge in breast conserving surgery is the high rates of re-excision due to positive resection margins. This study evaluates whether a combined diffuse reflectance spectroscopy (DRS) and laser induced intrinsic fluorescence spectroscopy (IFS) technique can differentiate breast tissue sample types, towards the development of an intraoperative margin assessment tool.</p><p><strong>Methods: </strong>Breast tissue samples were collected from patients undergoing breast cancer surgery. A handheld DRS-IFS probe was used on the frozen thawed ex-vivo  breast samples to acquire spectral data. Machine learning classifiers were used to determine sensitivity, specificity, overall diagnostic accuracy, and the area under the curve (AUC) against \"gold-standard\" histopathology ground truth.</p><p><strong>Results: </strong>181 breast tissue samples from 138 patients were interrogated using DRS-IFS. All patients were female, with median age (range) of 56.8 (20-94) years The total number of spectra acquired was 18,349. Following five-fold cross validation for normal versus cancer tissue, extreme gradient boost classifier achieved a sensitivity of 84% (SD ± 13), specificity of 61% (SD ± 16), overall diagnostic accuracy of 75% (SD ± 3), and AUC of 84%.</p><p><strong>Conclusion: </strong>The results suggests that DRS-IFS can distinguish normal breast tissue from breast cancer with high diagnostic accuracy. For DRS-IFS to be translated into the operating theatre to aid a surgeon's real-time visualisation for oncologic margin control assessment of intraoperative, the in vivo diagnostic accuracy needs to be determined.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"25-36"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Worse prognosis for breast cancer diagnosed in advanced pregnancy and shortly postpartum: an update of the Dutch pregnancy-associated breast cancer cohort.","authors":"Carsten F J Bakhuis, Stefan Preković, Britt B M Suelmann, Janneke Verloop, Pieter J Westenend, Sabine C Linn, Paul J van Diest, Elsken van der Wall, Carmen van Dooijeweert","doi":"10.1007/s10549-025-07806-3","DOIUrl":"10.1007/s10549-025-07806-3","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer diagnosed during pregnancy (PrBC) or postpartum (PPBC) is associated with a poorer prognosis, and earlier research indicated that outcomes differ based on timing of diagnosis. We updated and expanded our Dutch nationwide pregnancy-associated breast cancer (PABC) cohort, now also including patients diagnosed within one year after an interrupted pregnancy (AABC), to compare disease characteristics and prognosis across PrBC-, PPBC- and AABC subgroups and to non-PABC patients.</p><p><strong>Methods: </strong>All breast cancer pathology reports of women < 45 years in the Netherlands (1988-2022) were screened to identify patients diagnosed with PrBC, PPBC (< 12 months postpartum) or AABC (< 12 months after pregnancy interruption). PABC patients were 1:3 matched on age and year of diagnosis to non-PABC breast cancer patients.</p><p><strong>Results: </strong>In our PABC cohort (N = 787), the majority was diagnosed during pregnancy (n = 471, 60%). Two distinct prognostic subgroups were observed: a favorable group including trimester 1 PrBC, PPBC 6-12 months postpartum and AABC, and an unfavorable group diagnosed later in pregnancy (trimesters 2 and 3) or shortly postpartum (< 6 months). PABC patients showed overall, in comparison to non-PABC controls, poorer histopathological characteristics (more grade III and triple negative tumors) and a significantly worse 5-year overall survival (77% vs. 85%), persisting in multivariable analysis (HR 1.6, 95% CI 1.06 - 2.33, P = 0.025).</p><p><strong>Conclusions: </strong>PABC patients diagnosed in advanced pregnancy or shortly postpartum are most at risk for aggressive histopathology and an unfavorable prognosis. This highlights the need for in-depth analyses between specific PABC subgroups to elucidate the etiologic mechanisms involved.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"191-204"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating clinical response to primary endocrine therapy in elderly breast cancer patients in routine practice.","authors":"Tessa L Dinger, José H Volders, Anne Kuijer, Johannes C Kelder, Annemiek Doeksen, Emily L Postma, Thijs van Dalen","doi":"10.1007/s10549-025-07809-0","DOIUrl":"10.1007/s10549-025-07809-0","url":null,"abstract":"<p><strong>Purpose: </strong>Endocrine therapy (ET) can be used as a definitive treatment in frail and elderly breast cancer patients who are unwilling or deemed unfit to undergo surgical treatment. This study evaluated the clinical response to ET as primary treatment in elderly patients with non-metastatic, oestrogen receptor (ER) positive breast cancer, by evaluating its effectiveness over time.</p><p><strong>Methods: </strong>Elderly patients (≥ 70 years) with ER-positive breast cancer who had been treated with ET as primary treatment between 2008 and 2015 in two Dutch hospitals were identified through the Netherlands Cancer Registry. The primary outcome was the objectively measured clinical response at various time intervals after initiation of ET.</p><p><strong>Results: </strong>Out of 122 patients (median age, 86 years), 100 (82%) received ET as definitive treatment, whereas 22 (18%) received ET as neo-adjuvant endocrine therapy. Over the 3-year observation period, 25% of patients had died and 29% underwent invasive local treatment. The overall response rate after 3 years was 14% for all 122 patients and 30% for the 56 patients who were still alive and had not undergone local treatment after 3 years.</p><p><strong>Conclusion: </strong>The observed clinical response to ET in a consistent proportion of patients over time suggests it may be a viable option for a selection of frail and elderly breast cancer patients with limited life expectancy.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"215-222"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between ESR1 polymorphisms (XbaI & PvuII) and breast cancer risk: a comprehensive meta-analysis of case-control studies.","authors":"Ishan Behlam, Amrit Sudershan, Indu Priya, Srishty Sudershan, Adesh K Saini, Ravi Sharma, Mohd Younis, Rachna Sabharwal, Pawan Kumar, Sunita Manhas, Parvinder Kumar","doi":"10.1007/s10549-025-07800-9","DOIUrl":"10.1007/s10549-025-07800-9","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is one of the most common malignancies worldwide with notable geographic variation in incidence and mortality. Its risk is shaped by both environmental and genetic factors. Among the genetic contributors, ESR1 intronic polymorphisms such as XbaI and PvuII have been associated with breast cancer susceptibility, though results across populations remain inconsistent.</p><p><strong>Aim: </strong>In light of these discrepancies, the present study aimed to comprehensively evaluate the association between ESR1 polymorphisms (XbaI and PvuII) and breast cancer risk using a meta-analytical approach, with particular attention to ethnicity-based subgroup effects and methodological rigor.</p><p><strong>Methods: </strong>A systematic review was conducted per PRISMA guidelines using PubMed, Semantic Scholar, and Google Scholar. Twenty-six studies on XbaI and 28 on PvuII polymorphisms were included based on set criteria. Genotype and allele data were extracted, with study quality checked via the Newcastle-Ottawa Scale. Studies deviating from Hardy-Weinberg Equilibrium were excluded. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated across multiple genetic models. Heterogeneity was evaluated using I² and Cochran's Q tests, while Egger's and Begg's tests assessed publication bias. Sensitivity analyses tested the robustness of results.</p><p><strong>Results: </strong>Meta-analysis of ESR1 XbaI showed no significant association with breast cancer risk across all genetic models (e.g., allelic OR = 0.9957; p = 0.898), including ethnic subgroups (African, Asian, Caucasian). Moderate heterogeneity was noted, but sensitivity and publication bias analyses confirmed result stability. Similarly, ESR1 PvuII showed no overall association (e.g., allelic OR = 0.9755; p = 0.406); however, significant associations emerged in Africans (e.g., dominant OR = 1.7992; p = 0.012), suggesting ethnic-specific susceptibility.</p><p><strong>Discussion & conclusion: </strong>While ESR1 XbaI and PvuII polymorphisms are not associated with overall breast cancer risk, the PvuII variant may influence susceptibility in African populations. These findings highlight the need for large, multi-ethnic studies with standardized methods to clarify population-specific genetic risks.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"131-148"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Readability analysis of breast cancer resources shared on X-implications for patient education and the potential of AI.","authors":"Melanie J Wang, Aref Rastegar, Theodore A Kung","doi":"10.1007/s10549-025-07799-z","DOIUrl":"10.1007/s10549-025-07799-z","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;Breast cancer remains a global public health burden. This study aimed to evaluate the readability of breast cancer articles shared on X (formerly Twitter) during Breast Cancer Awareness Month (October 2024), and it explores the possibility of using artificial intelligence (AI) to improve readability.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We identified the top articles (n = 377) from posts containing #breastcancer on X during October 2024. Each article was analyzed using 9 established readability tests: Automated Readability Index (ARI), Coleman-Liau, Flesch-Kincaid, Flesch Reading Ease, FORCAST Readability Formula, Fry Graph, Gunning Fog Index, Raygor Readability Estimate, and Simple Measure of Gobbledygook (SMOG) Readability Formula. The study categorized sharing entities into five groups: academic medical centers, healthcare providers, government institutions, scientific journals, and all others. This comprehensive approach aimed to evaluate the readability of breast cancer articles across various sources during a critical awareness period of peak public engagement. A pilot study was simultaneously conducted using AI to improve readability. Statistical analysis was performed using SPSS.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 377 articles shared by the following entities were analyzed: academic medical centers (35, 9.3%), healthcare providers (57, 15.2%), government institutions (21, 5.6%), scientific journals (63, 16.8%), and all others (199, 53.1%). Government institutions shared articles with the lowest average readability grade level (12.71 ± 0.79). Scientific journals (16.57 ± 0.09), healthcare providers (15.49 ± 0.32), all others (14.89 ± 0.17), and academic medical centers (13.56 ± 0.39) had higher average readability grade levels. Article types were also split into different categories: patient education (222, 58.9%), open-access journal (119, 31.5%), and full journal (37, 9.6%). Patient education articles (15.19 ± 0.17) had the lowest average readability grade level. Open-access and full journals had an average readability grade level of 16.65 ± 0.06 and 16.53 ± 0.10, respectively. The mean values for Flesch Reading Ease Score are patient education 38.14 ± 1.2, open-access journals 16.14 ± 0.89, full journals 17.69 ± 2.14. Of note, lower readability grade levels indicate easier-to-read text, while higher Flesch Reading Ease scores indicate more ease of reading. In a demonstration using AI to improve readability grade level of 5 sample articles, AI successfully lowered the average readability grade level from 12.58 ± 0.83 to 6.56 ± 0.28 (p &lt; 0.001).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our findings highlight a critical gap between the recommended and actual readability levels of breast cancer information shared on a popular social media platform. While some institutions are producing more accessible content, there is a pressing need for standardization and improvement across all sources. To address this issue, s","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"121-130"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant response stratification based on complete, partial, and no response in HR-positive/HER2-positive breast cancer.","authors":"Ahmet Necati Sanli, Bilal Turan, Deniz Esin Tekcan Sanli, Isa Karaca, M Kadri Altundag, Fatih Aydogan","doi":"10.1007/s10549-025-07812-5","DOIUrl":"10.1007/s10549-025-07812-5","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the prognostic relevance of stratified pathological response -complete response (CR), partial response (PR), and no response (NR)- to neoadjuvant chemotherapy (NAC) in patients with hormone receptor-positive and HER2-positive (HR + /HER2 +) breast cancer.</p><p><strong>Methods: </strong>A total of 8277 HR + /HER2 + breast cancer patients treated with NAC between 2010 and 2021 were retrospectively identified from the SEER database. Patients were categorized into CR, PR, and NR groups. Overall survival (OS) and disease-specific survival (DSS) were analyzed using Kaplan-Meier and Cox regression models.</p><p><strong>Results: </strong>CR, PR, and NR rates were 52.3%, 41.4%, and 6.2%, respectively. Five-year OS rates were 96.3% (CR), 91.1% (PR), and 79.3% (NR), while 10-year DSS rates were 94.0% (CR), 83.4% (PR), and 76.2% (NR) (p < 0.001). In multivariate analysis, PR and NR were associated with significantly increased mortality risk compared to CR (OS HR: 2.16 and 4.20; DSS HR: 2.95 and 5.46; all p < 0.001). Progesterone receptor (PrgR) negativity independently predicted worse OS and DSS, whereas ER status had no significant impact. Additional adverse prognostic factors included advanced age, nodal metastasis, rural residence, and mastectomy. Radiotherapy did not retain significance in multivariate models.</p><p><strong>Conclusion: </strong>Pathological response to NAC is a strong independent prognostic marker in HR + /HER2 + breast cancer. Partial responders represent a clinically distinct group with intermediate outcomes, highlighting the need for response-adapted therapeutic strategies beyond conventional staging systems.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"247-264"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144942870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptomic and microenvironment characteristics of triple-negative breast cancer under three different neoadjuvant treatment regimens.","authors":"Zhilin Liu, Zhen Liu, Miaozhou Wang, Yaobang Liu, Xiaofeng Zhou, Yongxin Li, Zijun Zhu, Jinming Li, Jingqi Han, Yujin Hou, Bowen Zhao, Weiwei Zhang, Fuxing Zhao, Dengfeng Ren, Zitao Li, Yongzhi Chen, Shifen Huang, Mengting Da, Xiaoyan Ma, Xiaofang Ma, Ronghua Wang, Qiuxia Dong, Liang Cui, Jing Bai, Guoshuang Shen, Jiuda Zhao","doi":"10.1007/s10549-025-07810-7","DOIUrl":"10.1007/s10549-025-07810-7","url":null,"abstract":"<p><strong>Background: </strong>Adding immunotherapy to chemotherapy can modestly improve the pathological complete response (pCR) rate in triple-negative breast cancer (TNBC), while our previous NeoSAC study demonstrated that combining anti-angiogenic therapy can further enhance pCR. However, research on the mechanisms underlying the efficacy differences and biomarker comparisons across these treatment regimens remains insufficient.</p><p><strong>Patients and methods: </strong>Female TNBC patients were consecutively enrolled into three groups: chemotherapy (chemo), chemo-immunotherapy (chemo-ICI), and chemo-immunotherapy-anti-angiogenesis (chemo-ICI-AA, from our NeoSAC study, NCT04722718). Efficacy and safety were compared, with RNA sequencing and immune microenvironment analyses conducted to explore mechanisms of efficacy differences and identify potential biomarkers.</p><p><strong>Results: </strong>The total pCR rates in the chemo, chemo-ICI, and chemo-ICI-AA groups were 43.3%, 60.0%, and 72.7%, respectively. Baseline immune profiles were similar across groups, with comparable stromal, immune, and GEP scores. In the chemo-ICI-AA group, higher CD8 + T cells, TH1 cells, and TIL infiltration in pCR patients suggested their potential as biomarkers. Enhanced cytolytic activity, pro-inflammatory pathways, T-cell costimulation, and oxeiptosis correlated with higher pCR rates in the chemo-ICI-AA group. Notably, oxeiptosis has emerged as a potential predictor of treatment response, especially in pCR patients from the chemo-ICI and chemo-ICI-AA groups. Additionally, ALK (p = 0.017) and ATP6V1C2 (p = 0.036) were identified as significant genes in the chemo-ICI-AA pCR group, with predictive value for pCR outcomes.</p><p><strong>Conclusion: </strong>Adding immunotherapy and anti-angiogenic therapy to chemotherapy progressively increased the pCR rate. We emphasized the critical role of differentially expressed genes and immune microenvironment changes in predicting treatment outcomes.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"223-238"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144942831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic features and contralateral breast cancer risk in BRCA1/2 pathogenic variant carriers: a multicenter registry study of Japanese women.","authors":"Kanae Taruno, Hiroki Den, Mieko Takeuchi, Mayuko Inuzuka, Masami Arai, Seigo Nakamura, Takanori Ishida","doi":"10.1007/s10549-025-07815-2","DOIUrl":"10.1007/s10549-025-07815-2","url":null,"abstract":"<p><strong>Purpose: </strong>This large-scale study presents the clinicopathological characteristics and cumulative incidence of contralateral breast cancer (CBC) in Japanese BRCA1/2 pathogenic variant carriers, including cases diagnosed after the implementation of national insurance coverage.</p><p><strong>Methods: </strong>We analyzed 2949 breast cancer cases from the registry database of the Japanese Organization of Hereditary Breast and Ovarian Cancer.</p><p><strong>Results: </strong>BRCA1 carriers predominantly developed triple-negative breast cancer, whereas BRCA2 carriers more frequently developed luminal-type tumors, with a younger age of onset observed in BRCA1 carriers. No significant clinicopathological differences were found between the age groups. The cumulative incidence of CBC was 10.0% at five years and 29.0% at 10 years among BRCA1 carriers and 14.0% at five years and 19.0% at 10 years among BRCA2 carriers. CBC was observed in all age groups, including older patients. These findings highlight the importance of individualized decision-making in surgical planning and surveillance strategies.</p><p><strong>Conclusions: </strong>This study included a broad age range of patients, reflecting real-world data following the expansion of insurance coverage in Japan. Further case studies and long-term follow-up are warranted. Our findings support the development of appropriate clinical care and preventive strategies for BRCA1/2 carriers in Japan.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"277-288"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of timing and breastfeeding on postpartum breast cancer diagnostic patterns and outcomes.","authors":"Daniella Klebaner, Natalie Park, Kimberly Stone, Fauzia Riaz, Susan Crowe, Melinda Telli, Carol Marquez, Kathleen Horst","doi":"10.1007/s10549-025-07796-2","DOIUrl":"10.1007/s10549-025-07796-2","url":null,"abstract":"<p><strong>Purpose: </strong>Postpartum breast cancers (PPBC) have a worse prognosis than other breast cancers, but the impact of timing postpartum (PP) and concurrent breastfeeding (BF) on diagnostic patterns and outcomes remains unclear.</p><p><strong>Methods: </strong>We analyzed 161 PPBC patients diagnosed from 2002 to 2014, hypothesizing that diagnosis < 2 years PP (vs 2-5 years) and concurrent BF (vs not BF) at diagnosis would be associated with delayed diagnosis. We compared 2-year PP patients (N = 60) and 2-5 year PP patients (N = 101), and subsequently, patients who were (n = 36) and were not (n = 24) BF at diagnosis among the 2-year PP group with respect to clinicopathologic characteristics, breastfeeding details, diagnostic patterns, and disease outcomes. Differences were evaluated using chi-square and Mann-Whitney tests. Kaplan-Meier analysis assessed overall survival (OS) and distant disease-free survival (DDFS).</p><p><strong>Results: </strong>Median follow-up was 54 months. Patients in the 2-year PP group were more likely to be BF at diagnosis (60% vs 7%, p < 0.001), and have their symptoms attributed to lactational change (37 vs 9%, p < 0.001). They were also diagnosed at a higher stage (43 vs 24% Stage III/IV, p = 0.01), had worse 5-year OS (79% vs 97%, p < 0.001), and DDFS (74% vs 93%, p = 0.003) compared to 2-5 year PP patients. Among 2-year PP patients, patients BF at diagnosis were more likely to be diagnosed with mastitis preceding diagnosis (31% vs 4%, p = 0.03), more often had their symptoms attributed to lactational change (58% vs 4%), trended toward higher stage at diagnosis (53 vs 29% Stage III/IV, p = 0.1), had significantly worse 5-year DDFS (62% vs 91%, p = 0.032), and trended toward worse OS (74% vs 86%, p = 0.08) compared to those not BF.</p><p><strong>Conclusions: </strong>Our findings suggest that early PPBC and BF at diagnosis are associated with diagnostic delay and higher stage at diagnosis, which may have implications for prognosis.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"79-86"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study.","authors":"Toshiaki Iwase, Nithya Sridhar, Megumi Kai, Wenli Dong, Yu Shen, Savitri Krishnamurthy, Anthony Lucci, H T Carisa Le-Petross, Azadeh Nasrazadani, Sadia Saleem, Rachel M Layman, Vincente Valero, Debasish Tripathy, Wendy A Woodward, Yee Chung Cheng, Faina Nakhlis, Jenifer R Bellon, Filipa Lynce, Naoto T Ueno","doi":"10.1007/s10549-025-07795-3","DOIUrl":"10.1007/s10549-025-07795-3","url":null,"abstract":"<p><strong>Purpose: </strong>Randomized clinical trials have shown no benefit from adding anthracyclines to neoadjuvant treatment for HER2-positive breast cancer; however, the efficacy in inflammatory breast cancer (IBC) is unknown. Here we compared pathologic response rates for preoperative regimens with or without anthracyclines in HER2-positive primary IBC.</p><p><strong>Methods: </strong>We retrospectively reviewed patients diagnosed with HER2-positive primary IBC in 2014-2021 who received neoadjuvant therapy and modified radical mastectomy at MD Anderson Cancer Center, IBC Network institutions and Dana-Farber Cancer Institute. The primary outcome was a pathological complete response (pCR) rate. Secondary outcomes included time to local or regional recurrence (TLRR), event-free survival (EFS), and overall survival (OS). Univariate and multivariable analyses were performed with adjustments for clinically relevant covariates.</p><p><strong>Results: </strong>Of the 101 patients included, 39 received docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP), and 62 (docetaxel, trastuzumab, pertuzumab, doxorubicin, and cyclophosphamide) received THP-AC regimen. Median follow-up time was 3.02 years. The pCR rates did not differ by regimen type (48.7% TCHP vs. 53.2% THP-AC, p = 0.659). Multivariable logistic regression adjusted for age and estrogen receptor positivity showed no association between pCR or regimen. The multivariable Cox model showed that the patients who received THP-AC had longer TLRR (hazard ratio [HR] 0.279, 95% CI 0.102-0.765, p = 0.0131) and EFS (HR 0.462, 95% CI 0.228-0.936, p = 0.032), with no difference in OS.</p><p><strong>Conclusion: </strong>These findings indicate that an anthracycline-containing neoadjuvant regimen is not associated with pCR, but may prolong disease control in patients with HER2-positive IBC. Further investigation of the optimal neoadjuvant regimen for such tumors is warranted.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"69-77"},"PeriodicalIF":3.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}